Sugi Predict

Sugi Predict / Compounds / SCHEMBL10140608

SCHEMBL10140608

SCHEMBL10140608

CC(C)C(=O)[C@@H](N)CC(N)=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRP O00591 2/20 0.36
▸ GABRD O14764 2/20 0.36
▸ GABRA1 P14867 2/20 0.36
▸ GABRB1 P18505 2/20 0.36
▸ GABRG2 P18507 2/20 0.36
▸ GABRB3 P28472 2/20 0.36
▸ GABRA5 P31644 2/20 0.36
▸ GABRA3 P34903 2/20 0.36
▸ GABRA2 P47869 2/20 0.36
▸ GABRB2 P47870 2/20 0.36
▸ GABRA4 P48169 2/20 0.36
▸ GABRE P78334 2/20 0.36
▸ GABRA6 Q16445 2/20 0.36
▸ GABRG1 Q8N1C3 2/20 0.36
▸ GABRG3 Q99928 2/20 0.36
▸ GABRQ Q9UN88 2/20 0.36
▸ SLC7A5 Q01650 1/20 0.36
▸ ALOX15 P16050 1/20 0.34
▸ BLM P54132 1/20 0.34
▸ PMP22 Q01453 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12132306 1.00 GABRP (0.36) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL13050663 1.00 GABRP (0.36) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL24996109 0.81 SLC7A5 (0.33) SLC7A5ALOX15BLMPMP22KMT2A
SCHEMBL16138530 0.81 SLC7A5 (0.33) SLC7A5ALOX15BLMPMP22KMT2A
SCHEMBL16018408 0.80 GABRP (0.36) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL10212359 0.80 GABRP (0.46) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL4397917 0.80 GABRP (0.46) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL21790235 0.80 ALDH1A1 (0.48) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL12132308 0.80 GABRP (0.46) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL17810229 0.80 ALDH1A1 (0.48) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365577-A1 Photodynamic Therapy and Diagnosis RMW CHO GROUP LIMITED (HK) 2023-11-16 — — US disclosed
US-20230365577-A1 Photodynamic Therapy and Diagnosis RMW CHO GROUP LIMITED (HK) 2023-11-16 — — US disclosed
WO-2023086557-A1 NUCLEOSIDES FOR THE TREATMENT OF DNA VIRUS INFECTIONS EMORY UNIVERSITY (US) 2023-05-19 — — WO disclosed
WO-2022174179-A9 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO EMORY UNIVERSITY (US) 2023-02-02 — — WO disclosed
US-11331331-B2 N4-hydroxycytidine and derivatives and anti-viral uses related thereto EMORY UNIVERSITY (US) 2022-05-17 — — US disclosed
US-20220016153-A1 N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-01-20 — — US disclosed
US-20220017535-A1 INHIBITORS OF ALDOSE REDUCTASE BARCLAYS BANK PLC (GB) 2022-01-20 — — US disclosed
US-11197882-B2 — — 2021-12-14 — — US disclosed
EP-3728218-B1 AMINO INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2021-12-01 — — EP disclosed
US-11147826-B2 — — 2021-10-19 — — US disclosed
WO-2011081918-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC (US) 2011-07-07 — — WO disclosed
WO-2011031904-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC (US) 2011-03-17 — — WO disclosed
WO-2011031934-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2011-03-17 — — WO disclosed
WO-2010148006-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2010-12-23 — — WO disclosed
WO-2010099527-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2010-09-02 — — WO disclosed
WO-2010096462-A1 LINKED DIIMIDAZOLE DERIVATIVES ENANTA PHARMACEUTICALS, INC (US) 2010-08-26 — — WO disclosed
WO-2010091413-A1 LINKED DIBENZIMIDAZOLE DERIVATIVES ENANTA PHARMACEUTICALS, INC. (US) 2010-08-12 — — WO disclosed
US-7407803-B2 Immunogenic composition comprising bacterial or viral vector, antigen and toxins; escherichia and baculovirus; vaccines WYETH 2008-08-05 — — US disclosed
US-20070253971-A1 Immunogenic composition of vector; diagnostic immunoassays, probes and primers; host cells, genetic vaccines; administering to pregnant pigs WYETH 2007-11-01 — — US disclosed
WO-2007083984-A1 CONJUGATE COMPRISING PHARMACEUTICAL ACTIVE COMPOUND COVALENTLY BOUND TO MUCOADHESIVE POLYMER AND TRANSMUCOSAL DELIVERY METHOD OF PHARMACEUTICAL ACTIVE COMPOUND USING THE SAME GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2007-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11331331-B2 N4-hydroxycytidine and derivatives and anti-viral uses related thereto ENTPD1, NME2, NME1 GABRP 3493/4885GABRD 3952/4885GABRA1 3099/4885
US-20220017535-A1 INHIBITORS OF ALDOSE REDUCTASE PMM2, DPM1, BPGM GABRP 4801/4885GABRD 4490/4885GABRA1 4505/4885
US-11147826-B2 — SNRPE, NME2, NME1 GABRP 3152/4885GABRD 3845/4885GABRA1 2527/4885
US-20220016153-A1 N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO ENTPD1, NME2, NME1 GABRP 3493/4885GABRD 3952/4885GABRA1 3099/4885
US-11197882-B2 — SNRPE, NME2, NME1 GABRP 3152/4885GABRD 3845/4885GABRA1 2527/4885
US-20230365577-A1 Photodynamic Therapy and Diagnosis PPOX, PPIF, ALAD GABRP 2335/4885GABRD 3677/4885GABRA1 3850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.